Hepion Pharmaceuticals’ Product CRV431 Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.

Hepion Pharmaceuticals
CRV431 Decreased Liver Fibrosis and Tumor Burden in Experimental Models
EDISON, NJ / ACCESSWIRE / October 16, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.